Member of the Board of Directors and R&D/Science Chair Dr. Kim Blackwell is serving on the board of directors of Fore since September 2021.
Dr. Kimberly Blackwell is a pioneering oncology leader and breast cancer researcher recognized as one of TIME Magazine’s 100 Most Influential People in the World for her groundbreaking work developing targeted therapies such as lapatinib and T-DM1 for HER2+ breast cancer. With more than 20 years of experience in drug development and clinical innovation, she is the Founder of Key Oncology Consulting, advising early-stage biotech companies on precision oncology and transformative therapeutic strategies.
Previously, Dr. Blackwell served as CEO and Board Member of Zentalis Pharmaceuticals, advancing novel therapies for Cyclin E-driven solid tumors, and as Chief Medical Officer at Tempus AI, where she led precision medicine and AI-driven oncology initiatives. She also held senior leadership roles at Eli Lilly, where she was recognized as one of Endpoints News’ “Twenty Extraordinary Women in Biopharma R&D.”
A former faculty member at the Duke University Cancer Institute, Dr. Blackwell has led over 50 clinical trials and co-founded the radiotherapeutics company Cereius. She currently also serves on the Boards of Century Therapeutics (Nasdaq: IPSC), Monte Rosa Therapeutics (Nasdaq: GLUE)
